Targeting the Synthetic Vulnerability of PTEN-Deficient Glioblastoma Cells with MCL1 Inhibitors.
Chen C, Zhu S, Zhang X, Zhou T, Gu J, Xu Y, Wan Q, Qi X, Chai Y, Liu X, Chen L, Yan J, Hua Y, Lin F.
Chen C, et al. Among authors: zhang x.
Mol Cancer Ther. 2020 Oct;19(10):2001-2011. doi: 10.1158/1535-7163.MCT-20-0099. Epub 2020 Jul 31.
Mol Cancer Ther. 2020.
PMID: 32737157